Obviously we believe that we do have a product that actually allows you to be more efficient from a cost perspective because the product should induce less toxicity with far less patient management. With that, I think there should be a good, healthy economic argument supporting the use of obe-cel in addition to obviously its clinical profile. With regards to Europe, we’re obviously seeing across the board with CAR T therapy that the prices are starting in the range of where the U.S. prices are, with some level of discount depending on the jurisdictions you’re looking at and the indication that the products are delivering, so that is more variable and we’ll see how that develops over the upcoming period of time. We will keep you updated how that field evolves over time, but I think this is where we stand, and the current expectation is that we would consider to be somewhere in line with what we can see in the space.
In terms of data flow, I think we’re going to have a very interesting data flow as we go through this year. Obviously at ASCO, obviously the data from all the patients that were dosed but also still a limited follow-up on some of the patients, that I think the focus on a lot of the descriptions of the patients, the basic activity, the behavior of the product in every aspect, and then I think as we go to ASH and then even later into ’24, I think much more longer term follow-up which I think will flow obviously as an important parameter into the assessments and value assessments that will be conducted by the payors, so that’s kind of, I think, where we are with those particular questions.
Karina Rabayeva: Do you think the longer term follow-up is going to push pricing higher?
Christian Itin: Well first of all, the impact of the longer term follow-up, by showing an impact on longer term follow-up I think is obviously strengthening your value argument for the product, so I think it will clearly make a very strong case for using the product based on more patients achieving long term outcome, and I think that is certainly going to be a key parameter that will drive the value assessment by anyone who would look at the program, so it will definitely influence the overall assessment. To what extent that would influence pricing, I think it’s premature to discuss.
Karina Rabayeva: Okay, thank you.
Christian Itin: Thank you Karina.
Operator: Thank you. At this time, I’d like to turn the call back over to Mr. Christian Itin for closing remarks.
Christian Itin: Well first of all, thanks everybody for joining. Obviously it was great to be able to update you on t he very exciting fourth quarter that we are running through. We’re in, I think, a very important stretch as we go through the course of this year, getting the product ready for filings, and I think obviously a real opportunity for substantive data updates as we go through the course of the year, with the next ones expected for the midyear section, so really looking forward to meeting you hopefully in person and updating you on the program along those venues, and successful first half of the year, and then I think for all of us, I think a more relaxed second half of the year with some hope that some of the big picture items hopefully will start to turn into a more favorable environment. With that, I’d like to thank you all and wish you a good day.
Operator: Ladies and gentlemen, thank you for your participation, and due to time limitations, we were conscious of the time and we weren’t able to reach out to everyone, so management will connect with everyone that wasn’t able to connect to the call, after the call. Thank you very much. Please enjoy your day. You may now disconnect.
